在COPD频繁恶化患者中,脂质媒介的调节失调
Marie Fisk1,2, Esteban A Gomez3, Yuan Sun2
1Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
ERJ open research
|March 25, 2025
概括
在COPD患者中,专门的亲解决媒介 (SPMs) 的调节失调. 在患有频繁恶化和预测未来严重事件的患者中发现了较低水平的SPM,特别是D-溶解.
科学领域:
- 生物化学 生物化学
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
背景情况:
- 专门的亲溶解媒介 (SPMs) 是脂质媒介 (LMs),对于解决炎症和促进组织修复至关重要.
- SPM的失调可能有助于慢性阻塞性肺病 (COPD) 的病理生理学.
研究的目的:
- 研究与健康对照组相比,COPD患者的SPM产生是否发生变化.
- 为了确定SPM概况是否在稳定的COPD患者和经历频繁恶化的患者之间有所不同.
- 探索LM形状与严重COPD恶化的风险之间的关联.
主要方法:
- 脂质介质 (LMs) 在血中从稳定的COPD患者,频繁恶化的COPD患者和使用液体染色学-并列质谱法 (LC-MS/MS) 的健康对照进行量化.
- 在这三个组中,LM的个人资料进行了比较.
- 统计分析探讨了LM水平和恶化史之间的关联.
主要成果:
- 稳定的COPD患者与对照人群相比,表现出更多的促炎媒介和一些SPM.
- 患有频繁恶化的患者表现出较低的前列腺素 (PG) D2和SPM水平 (包括D-resolvins和脂素) 比稳定的COPD患者.
- 频繁恶化症患者的较低D-溶水平独立地与随访期间严重恶化的风险增加有关.
结论:
- 显著的脂质介导体概况标志着稳定的COPD和频繁的恶化COPD表型.
- 患有频繁恶化COPD患者的D-resolvins下调与未来严重恶化的风险增加有关.
- 需要进一步的研究来阐明这些调解者在COPD恶化中的确切作用.
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
163
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
163
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
01:22Chronic Obstructive Pulmonary Disease
1.1K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.1K
01:20COPD: Pathogenesis and Clinical Features
218
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
218
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
01:17Drugs Used in Lower Respiratory Disorders: Overview
320
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
320